UroGen Pharma (URGN) 10-Q 7 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 04, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	URGN
Title of 12(b) Security	Ordinary Shares, par value NIS 0.01 per share
Security Exchange Name	NASDAQ
Entity Registrant Name	UROGEN PHARMA LTD.
Entity Central Index Key	0001668243
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Ordinary Shares Outstanding		21,935,131
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38079
Entity Incorporation, State or Country Code	L3
Entity Tax Identification Number	98-1460746
Entity Address, Address Line One	400 Alexander Park Drive
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	646
Local Phone Number	768-9780

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 26,468	$ 49,688
Marketable securities	92,623	97,389
Restricted cash	1,223	523
Prepaid expenses and other current assets	1,552	1,034
TOTAL CURRENT ASSETS	121,866	148,634
NON-CURRENT ASSETS
Property and equipment, net	991	977
Restricted deposit	223	223
Right of use asset	3,433	3,735
Marketable securities	40,137	48,555
Other non-current assets	279	264
TOTAL ASSETS	166,929	202,388
CURRENT LIABILITIES:
Accounts payable and accrued expenses	8,500	11,186
Employee related accrued expenses	4,075	6,711
Other current liabilities	1,632	1,585
TOTAL CURRENT LIABILITIES	14,207	19,482
NON-CURRENT LIABILITIES:
Long-term lease liability	2,268	2,604
TOTAL LIABILITIES	16,475	22,086
COMMITMENTS AND CONTINGENCIES (Note 14)
SHAREHOLDERS’ EQUITY:
Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at March 31, 2020 and December 31, 2019; 21,212,940 and 21,026,184 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	58	57
Additional paid-in capital	415,895	407,986
Accumulated deficit	(265,810)	(228,017)
Accumulated other comprehensive income	311	276
TOTAL SHAREHOLDERS’ EQUITY	150,454	180,302
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 166,929	$ 202,388

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (unaudited) - ₪ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Ordinary shares, par value	₪ 0.01	₪ 0.01
Ordinary shares, shares authorized	100,000,000	100,000,000
Ordinary shares, issued	21,212,940	21,026,184
Ordinary shares, outstanding	21,212,940	21,026,184

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
OPERATING EXPENSES:
RESEARCH AND DEVELOPMENT EXPENSES	$ 16,588	$ 9,726
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	21,973	12,707
OPERATING LOSS	(38,561)	(22,433)
INTEREST AND OTHER INCOME, NET	768	989
NET LOSS	(37,793)	(21,444)
STATEMENTS OF COMPREHENSIVE LOSS
NET LOSS	(37,793)	(21,444)
OTHER COMPREHENSIVE INCOME:
UNREALIZED GAIN ON MARKETABLE SECURITIES	35
COMPREHENSIVE LOSS	$ (37,758)	$ (21,444)
NET LOSS PER ORDINARY SHARE BASIC AND DILUTED	$ 1.79	$ 1.11
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE	21,158,161	19,340,082

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (unaudited) - USD ($) $ in Thousands	Total	Ordinary Shares	Additional Paid-In Capital	Accumulated Deficit	Other Comprehensive Income
Balance at Dec. 31, 2018	$ 90,094	$ 44	$ 212,921	$ (122,871)
Balance,Share at Dec. 31, 2018		16,214,883
Exercise of options into ordinary shares	2,047	$ 1	2,046
Exercise of options into ordinary shares, shares		336,148
Share-based compensation	7,447		7,447
Issuance of ordinary shares in public offering, net of issuance expenses	161,447	$ 11	161,436
Issuance of ordinary shares in public offering, net of issuance expenses, shares		4,207,317
Net loss	(21,444)			(21,444)
Balance at Mar. 31, 2019	239,591	$ 56	383,850	(144,315)
Balance,Share at Mar. 31, 2019		20,758,348
Balance at Dec. 31, 2019	180,302	$ 57	407,986	(228,017)	$ 276
Balance,Share at Dec. 31, 2019		21,026,184
Exercise of options into ordinary shares	293	$ 1	292
Exercise of options into ordinary shares, shares		186,756
Share-based compensation	7,617		7,617
Other comprehensive income	35				35
Net loss	(37,793)			(37,793)
Balance at Mar. 31, 2020	$ 150,454	$ 58	$ 415,895	$ (265,810)	$ 311
Balance,Share at Mar. 31, 2020		21,212,940

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (37,793)	$ (21,444)
Adjustment to reconcile net loss to net cash from operating activities:
Depreciation and amortization	82	63
Amortization/Accretion on marketable securities	98
Stock-based compensation	7,617	7,447
Amortization of right of use asset	374	245
Lease liability	(361)	(173)
Changes in operating assets and liabilities:
Increase in prepaid expenses and other current assets	(518)	(41)
Decrease in accounts payable and accrued expenses	(2,498)	(2,440)
Decrease in employee related accrued expenses	(2,636)	(1,591)
Net cash used in operating activities	(35,635)	(17,934)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of marketable securities	(9,378)
Maturities of marketable securities	22,499
Purchases of property and equipment	(96)	(44)
Net cash provided by (used in) investing activities	13,025	(44)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of options into ordinary shares	293	1,532
Issuance of ordinary shares, net of issuance expenses		161,974
Issuance cost for shelf filing	(203)
Net cash provided by financing activities	90	163,506
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(22,520)	145,528
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD	50,211	101,571
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE PERIOD	27,691	247,099
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Non-cash new lease liabilities	$ 72
Non-cash issuance cost		312
Exercise of options		$ 515

Business and Nature of Operatio

Business and Nature of Operations	3 Months Ended
	Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Business and Nature of Operations	NOTE 1-BUSINESS AND NATURE OF OPERATIONS Nature of Operations UroGen 0 UroGen wholly owned a n UPL o l g On April 15, 2020, the U.S. Food and Drug Administration (“FDA”) granted expedited approval for Jelmyto (mitomycin), for pyelocalyceal solution, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“LG-UTUC”). See Note 15 for further details.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	NOTE 2-BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary to state fairly the financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (“SEC”) on March 2, 2020. The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation. The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and has an accumulated deficit of $265.8 million and $228.0 million as of March 31, 2020 and December 31, 2019, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it expands its portfolio and engages in further research and development activities, particularly conducting nonclinical studies, clinical trials and preparing for the potential commercial launch of The success of the Company depends on its ability to develop its technologies to the point of U.S. Food and Drug Administration ( “ ”

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 3-SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation. Use of Estimates The a i i n a i Functional The p l Accordingly, l n i a condensed a ( Cash and Cash Equivalents; Marketable Securities The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. Cash and cash equivalents and marketable securities totaled $159.2 million as of March 31, 2020. The Company classifies its marketable securities as available-for-sale in accordance with the Financial Accounting Standards Board (“ Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes. Concentration of Credit Risk Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company ’ The Company ’ Income Taxes The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which we operate. Deferred l e n s a a The n l w a Property and Equipment Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3-6.5 Furniture 5-16.5 Manufacturing equipment 2 Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 7 for further discussion regarding property and equipment. Leases The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases. The Company accounts for leases in accordance with ASC Topic 842, “Leases” . Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments. The Company’s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option. Because most of the Company’s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The Company has lease agreements with lease and non-lease components. We applied the modified retrospective transition method and elected the transition option to use the effective date of January 1, 2019 as the date of initial application (“Transition Date”). ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, “Property, Plant, and Equipment”, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Revenues To date, the Company has derived virtually all its revenues from its license and supply agreement (the “Allergan Agreement”) with Allergan Pharmaceuticals International Limited (“Allergan”), a wholly owned subsidiary of Allergan plc. Under the Allergan Agreement, the Company granted Allergan an exclusive license to develop, commercialize, and otherwise exploit products that contain reverse thermal hydrogel (“RTGel”) and agreed to supply Allergan with pre-clinical and clinical quantities of the RTGel product, also referred to as the RTGel Research and Development Expenses Research s i d a l l Selling General and Administrative Expenses Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, executives, finance, commercial, medical affairs, business development, investor relations and human resources functions). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known. Share-Based Compensation Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (“RSU”) equaled the closing price of our ordinary shares on the grant date. The Company accounts for forfeitures as they occur according to the FASB’s Accounting Standards Update (ASU) 2016-09, Improvements to Employee Share-Based Payment Accounting. The Company elected to recognize compen s ation costs for awards conditioned only on conti n ued service that have a graded vesting schedule using the straight-line method and to value the awards based on the sin g le-option award approach. Net Loss per Ordinary Share Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 requires the Company to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the Company’s current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the prior other-than-temporary impairment model. The Company applied the modified retrospective transition method as of the date of initial application, January 1, 2020, or the Transition Date. As of March 31, 2020, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period.

Other Financial Information

Other Financial Information	3 Months Ended
	Mar. 31, 2020
Other Financial Information [Abstract]
Other Financial Information	NOTE 4-OTHER FINANCIAL INFORMATION Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following as of March 31, 2020 and December 31, 2019 (in thousands): March 31, 2020 December 31, 2019 Accounts payable $ 4,152 $ 4,694 Accrued clinical expenses 235 399 Accrued research and development costs 1,696 2,644 Accrued selling, general and administrative expenses 2,057 2,767 Accrued other expense 360 682 Total accounts payable and accrued expenses $ 8,500 $ 11,186 Interest and Other (Income) Expenses, Net Interest and other (income) expenses consisted of the following as of March 31, 2020 and 2019 (in thousands): Three Months Ended March 31, 2020 2019 Interest income $ (811 ) $ (1,010 ) Other finance expenses 43 21 Total finance income $ (768 ) $ (989 )

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 5-FAIR VALUE MEASUREMENTS The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs that reflect the reporting entity ’ The carrying amounts of the Company ’ Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of March 31, 2020 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable March 31, Identical Assets Inputs 2020 (Level 1) (Level 2) Marketable securities: US government $ 68,414 $ 68,414 $ — Corporate bonds 55,671 — 55,671 Commercial paper (1) 8,486 — 8,486 Money market funds (2) 13,904 13,904 — Certificates of deposit 1,788 — 1,788 $ 148,263 $ 82,318 $ 65,945 (1) $1.6 million is included within cash and cash equivalents on the condensed consolidated balance sheets (2) Included within cash and cash equivalents on the condensed consolidated balance sheets. Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2019 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable December 31, Identical Assets Inputs 2019 (Level 1) (Level 2) Marketable securities: US government $ 66,094 $ 66,094 $ — Corporate bonds 68,084 — 68,084 Commercial paper 7,658 — 7,658 Money market funds (1) 16,998 16,998 — Certificates of deposit 4,108 — 4,108 $ 162,942 $ 83,092 $ 79,850 (1) Included within cash and cash equivalents on the condensed consolidated balance sheets. The Company ’

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2020
Investments Debt And Equity Securities [Abstract]
Marketable Securities	NOTE 6-MARKETABLE SECURITIES The following table summarizes the Company’s marketable securities as of March 31, 2020 (in thousands): Amortized Cost Basis Unrealized Gains Unrealized Losses Fair Value Marketable securities: US government $ 67,648 $ 766 $ — $ 68,414 Corporate bonds 56,135 75 (539 ) 55,671 Commercial paper 8,480 6 — 8,486 Money market funds 13,904 — — 13,904 Certificates of deposit 1,785 3 — 1,788 $ 147,952 $ 850 $ (539 ) $ 148,263 The Company classifies its marketable securities as available-for-sale and they consist of all debt securities. The amortized cost basis as of March 31, 2020 includes $0.6 million of accrued interest receivable . Unrealized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss. As of March 31, 2020 As of March 31, 2020, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period. The Company’s marketable securities as of March 31, 2020 mature at various dates through February 2022. The fair values of marketable securities by contractual maturity consist of the following (in thousands): March 31, 2020 December 31, 2019 Maturities within one year $ 108,126 $ 114,386 Maturities after one year through three years 40,137 48,556 $ 148,263 $ 162,942

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2020
Property Plant And Equipment [Abstract]
Property and Equipment	NOTE 7-PROPERTY AND EQUIPMENT Property and equipment, consists of the following as of March 31, 2020 and December 31, 2019 (in thousands): March 31, 2020 December 31, 2019 Laboratory equipment $ 264 $ 259 Computer equipment and software 455 416 Furniture 596 544 Leasehold improvements 530 530 Manufacturing equipment 226 226 2,071 1,975 Less: accumulated depreciation and amortization (1,080 ) (998 ) Property and equipment, net $ 991 $ 977 Depreciation and amortization expenses were $0.1 million and $0.1 million for the three months ended March 31, 2020 and 2019, respectively.

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	NOTE 8-LEASES Operating Leases The Company has the following office and laboratory facility leases: • In April 2016, UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022. • In September 2017, UPI entered into a new lease agreement for its office space in New York, which the Company previously used as its headquarters. The lease agreement commenced in October 2017 and terminates in February 2021. The Company’s remaining contractual obligation under this lease is approximately $0.6 million as of March 31, 2020. • In April 2018, UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was July 10, 2018 and terminates in March 2024. The landlord provided a tenant allowance for leasehold improvements of $0.2 million that was accounted for as a lease incentive. The Company’s remaining contractual obligation under this lease is approximately $1.1 million as of March 31, 2020. In November 2019, UPI entered into a sublease for this office space, with a lease commencement date of January 1, 2020 and continuing until the end of the lease term in March 2024. The subtenants exercised their early access clause and moved into the premises the end of November 2019. The remaining rental payments to be received over the lease term is approximately $0.8 million as of March 31, 2020 . The Company accounts for the sublease as on operating lease in accordance with ASC 842-10-25-2 and ASC 842-10-25-3. The main lease was considered for impairment and the amount was determined to be immaterial. • In November 2019, UroGen Pharma Inc. entered into a new lease agreement for an office in Princeton, NJ, which the Company now uses as its headquarters. The lease commencement date was November 29, 2019 and the lease term is 38 months. The Company’s remaining contractual obligation under this lease is approximately $1.6 million as of March 31, 2020. In addition, the Company has other operating office equipment and vehicle leases. The Company’s operating leases may require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company’s leases do not contain any residual value guarantees or material restrictive covenants. The Company’s leases expire at various dates from 2019 through 2023, with varying renewal and termination options. The components of lease cost for the three months ended March 31, 2020 were as follows (in thousands) Three Months Ended March 31, 2020 Operating lease cost $ 430 Sublease income (56 ) Variable lease cost 56 $ 430 The amounts recognized as of March 31, 2020 were as follows (in thousands): March 31, 2020 Right of use asset $ 3,433 Long-term lease liability 2,268 Other current liabilities 1,632 As of March 31, 2020, no impairment losses have been recognized to date. Supplemental information related to leases for the periods reported is as follows (in thousands): Three Months Ended March 31, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 390 Right-of-use assets obtained in exchange for new operating lease liabilities 180 Weighted-average remaining lease term of operating leases 2.73 years Weighted-average discount rate of operating leases 5.47% Subleases As of March 31, 2020 undiscounted cash flows to be received under the Company’s operating sublease on an annual basis was as follows (in thousands): Operating Leases Years ending December 31, Remainder of 2020 $ 61 2021 235 2022 243 2023 251 2024 49 2025 and thereafter — $ 839 Sublease income is recognized net within operating expenses. Sublease income for the three months ended March 31, 2020 was as follows (in thousands): Three Months Ended March 31, 2020 Sublease income from fixed lease payments $ 56 Sublease income from variable payments — $ 56

License and Collaboration Agree

License and Collaboration Agreements	3 Months Ended
	Mar. 31, 2020
Liscense Agreement [Abstract]
License and Collaboration Agreements	NOTE 9-LICENSE AND COLLABORATION AGREEMENTS Allergan Agreement In October 2016, the Company entered into the Allergan Agreement and granted Allergan an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX ® Under the Allergan Agreement, Allergan is solely responsible for costs and development of the Licensed Products and obtaining all regulatory approvals for Licensed Products worldwide, as well as worldwide commercialization of the Licensed Products after receiving the regulatory approval to do so. Allergan is required to use commercially reasonable efforts to develop and commercialize the Licensed Products for overactive bladder in certain major market countries. The Company will supply Allergan with certain quantities of RTGel for development of Licensed Products through Phase 2 clinical trials using BOTOX together with RTGel in patients with overactive bladder, at Allergan’s request and expense. Allergan has the right to reduce the next milestone payment if there is a material supply failure from the Company. Prior to completion of the first Phase 2 clinical trial, Allergan has the right to request that the Company transfers to Allergan our manufacturing process for RTGel and Allergan will assume the responsibility to manufacture RTGel and Licensed Product for its own development and commercialization activities. Further, the Company is eligible to receive additional material milestone payments of up to an aggregate of $200.0 million upon the successful completion of certain development, regulatory and commercial milestones. As of March 31, 2020, since inception of the Allergan Agreement the Company has received a total of $25.0 million in milestone payments from Allergan. Allergan will pay the Company a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of our patent coverage of Licensed Products. The Company is responsible for payments to any third party for certain RTGel-related third-party intellectual properties. Under the Allergan Agreement, Allergan granted the Company a non-exclusive, sublicensable, fully paid-up, perpetual, worldwide license under any improvements Allergan makes to the composition, formulation, or manufacture of RTGel for the research, development, manufacture and commercialization of any product containing RTGel and any active ingredient (other than a clostridial toxin) for all indications other than indications covered by the agreement and an exclusive, sublicensable, royalty-bearing (in low single digits), perpetual worldwide license under such improvements for use in the prevention or treatment of oncology indications. The Company plans to continue to research, develop and commercialize other products combining RTGel with other active ingredients, except that there are certain restrictions with respect to the overactive bladder and neurogenic detrusor overactivity indications. Subject to provisions called out in the Allergan Agreement, Allergan may unilaterally terminate the Allergan Agreement for any reason upon advance notice. In addition, either party may terminate the Allergan Agreement for various reasons. Agenus Agreement In November 2019, the Company entered into a license agreement with Agenus Inc, pursuant to which Agenus granted to the Company an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus’s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary antibody of Agenus known as AGEN1884 for the treatment of cancers of the urinary tract via intravesical delivery. AGEN1884 is an anti-CTLA-4 antagonist that is currently being evaluated by Agenus as a monotherapy in PD-1 refractory patients and in combination with Agenus’ anti-PD-1 antibody in solid tumors. Initially, the Company plans to develop AGEN1884 in combination with UGN-201 for the treatment of high-grade non-muscle invasive bladder cancer. Pursuant to the license Agreement, the Company paid Agenus an upfront fee of $10.0 million and has agreed to pay Agenus up to $115.0 million upon achieving certain clinical development and regulatory milestones, up to $85.0 million upon achieving certain commercial milestones, and royalties on net sales of licensed products in the 14%-20% range. The Company will be responsible for all development and commercialization activities. Under the terms of the license agreement, Agenus has agreed to use commercially reasonable efforts to supply AGEN1884 to the Company for use in preclinical studies or clinical trials. Unless earlier terminated in accordance with the terms of the license agreement, the license agreement will expire on a product-by-product and country-bycountry basis at the later of (a) the expiration of the last to expire valid claim of a licensed patent right that covers the licensed product in such country or (b) 15 years after the first commercial sale of the licensed product in such country. The Company may terminate the license agreement for convenience upon 180 days’ written notice to Agenus. Either party may terminate the license agreement upon 60 days’ notice to the other party if, prior to the first commercial sale of a licensed product, the Company substantially ceases to conduct development activities of the licensed products for nine consecutive months (and during such period, Agenus has complied with its obligations under the license agreement) other than in response to a requirement of an applicable regulatory authority or an event outside of the Company’s control. In addition, either party may terminate the license agreement in the event of an uncured material breach of the other party. As of March 31, 2020, since inception of the Agenus Agreement, the Company has paid a total of $10.0 Early-Stage Feasibility Evaluation with Janssen Research & Development, LLC (“Janssen”) In April 2019, the Company entered into an agreement with Janssen to conduct an early-stage feasibility evaluation in a therapeutic area of mutual interest. The Company and Janssen will each conduct certain activities under the terms of the agreement, and the Company will incur the costs of its own efforts related to the feasibility evaluation. Under the agreement the parties agreed to conduct a limited scope of laboratory and animal testing work. On March 24, 2020 and based on results of the animal studies conducted under the MTA Janssen and UroGen mutually agreed to terminate the MTA and therefore recognize that no further work will be conducted by either party.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Shareholders' Equity	NOTE 10-SHAREHOLDERS’ EQUITY The Company had 100.0 million ordinary shares authorized for issuance as of March 31, 2020 and December 31, 2019, respectively. The Company had 21.2 million and 21.0 million ordinary shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively. Each d w (the “Board”) In January 2019, the Company completed an underwritten public offering of 4,207,317 of its ordinary shares, including 548,780 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $41.00 per share. The net proceeds to the Company from the offering were approximately $161.4 million, after deducting the underwriting discounts and commissions and payment of other offering expenses. In December 2019, the Company entered into a sales agreement (the “ATM Sales Agreement”) w ith Cowen and Company, LLC (“Cowen”), to or through Cowen, acting as sales agent or principal

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	NOTE 11-SHARE-BASED COMPENSATION In a The b d p l n e Certain management and professional level employees typically receive options and restricted stock units, or RSU, grants upon commencement of employment. Also, eligible employees may receive an annual grant of options or RSUs. Non-employee members of the Board and any new, future directors may receive a grant of RSUs and/or stock options annually. The term of any option granted under the Plan cannot exceed 10 years. Options shall not have an exercise price less than 100% of the fair market value of the Company’s ordinary shares on the grant date, and generally vest over a period of three years. If the individual possesses more than 10% of the combined voting power of all classes of equity of the Company, the exercise price shall not be less than 110% of the fair market value of an ordinary share on the date of grant. The Company’s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a 33% increment upon the first anniversary of grant, and in equal quarterly amounts for the two years following the one-year anniversary of the grant date. Options generally vest in a 33% increment upon the first anniversary of the grant date, and in equal quarterly amounts for the two years following the one-year anniversary of the grant date. The a mix of the Company’s historical volatility, and c e In March 2017, the Board adopted the 2017 Equity Incentive Plan (the "2017 Plan"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of incentive stock options to the Company's employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance share awards, performance cash awards, and other forms of share awards to the Company's employees, directors and consultants. The maximum number of ordinary shares that may initially be issued under the 2017 Plan is 1,400,000. In addition, the number of ordinary shares reserved for issuance under the 2017 Plan will automatically increase on January 1st of each calendar year, from January 1, 2018 through January 1, 2026, so that the number of such shares reserved for issuance will equal 12% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by the Board. The maximum number of ordinary shares that may be issued upon the exercise of stock options under the 2017 Plan is 5,600,000. On January 1, 2018, the share reserve increased by 250,167 to 1,650,167. On October 12, 2018, the Company increased the amount of registered ordinary shares of the Company’s 2017 Plan by 1,900,000 to 3,550,167. On January 3, 2019, the Company appointed Elizabeth Barrett as its President and Chief Executive Officer. In connection with Ms. Barrett’s employment, she was granted 277,432 options to purchase the Company’s ordinary shares, at an exercise price of $47.57, as well as 317,065 RSUs, with a combined grant-date fair value of $24.1 million. In May 2019, the Company adopted the UroGen Pharma Ltd. 2019 Inducement Plan (the “Inducement Plan”). Under the Inducement Plan, the Company is authorized to issue up to 900,000 ordinary shares pursuant to awards issued under the Inducement Plan. The only persons eligible to receive grants of Awards (as defined below) under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3) and the related guidance under Nasdaq IM 5635-1, including individuals who were not previously an employee or director of the Company or are following a bona fide period of non-employment, in each case as an inducement material to such individual’s agreement to enter into employment with the Company. Under the Inducement Plan, an “Award” is a nonstatutory stock option, restricted stock unit or other right to receive ordinary shares pursuant to the Inducement Plan. In June 2019, as part of the Company’s Annual Meeting of Shareholders, the Company’s Board of Directors approved grants of 70,000 options to its non-employee directors. Each then current non-employee director, including the Chairman of the Board, received a grant of 10,000 options. Each option is exercisable into one ordinary share of the Company’s stock at an exercise price of $34.83 per share. The options vest quarterly over one year and expire 10 years from grant date. The grant date fair value of these options was approximately $1.9 million. In December 2019, the Company’s board of directors approved a modification of options and RSU's for a consultant. The Company recorded an expense of $0.9 million under general and administrative expenses with respect to options' modification. No compensation expense was taken in relation to the RSUs modification because the award vests upon a future performance condition that is not currently probable of occurring. The p condensed consolidated Three Months Ended March 31, 2020 2019 Research and development expenses 1,943 2,338 Selling, general and administrative expenses 5,674 5,109 $ 7,617 $ 7,447 The total unrecognized compensation cost of options and RSUs a March 31, 2020 is $50.8 million with a weighted average recognition period of 1.95 years.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 12-INCOME TAXES UroGen Pharma Ltd.

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Parties	NOTE 13-RELATED PARTIES There were no related party transactions for the three months ended March 31, 2020 or the three months ended March 31, 2019.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 14-COMMITMENTS AND CONTINGENCIES In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company ’ ’ Grants Israeli Innovation Authority in Israel (“ The n Israeli d On January 12, 2020, the IIA Office of Chief Scientist approved the Company's request to unwind its obligation to the IIA regarding grants that were loaned to the Company between January 2004 and September 2016. The total payment under the IIA approval, net of the royalties already paid, $6.6 million, was fully paid during the first quarter of 2020 and recognized as research and development expense. Based on this payment, the company will have full freedom to transfer IIA-funded technology or manufacture products developed with IIA-funded technology outside of the State of Israel. Other than the commitment to continue at least 75% of its based R&D jobs in Israel (at the time of settlement) for a period of at least three years, all other obligations with the IIA ceased to exist as per the agreement. On March 20, 2020, the Company entered into a Separation Agreement with Stephen Mullennix, the Company’s Chief Operating Officer, which sets forth the terms of Mr. Mullennix’s termination of employment with the Company, effective as of April 30, 2020, or Separation Date. The arrangement includes cash severance, as well as a pro rata portion of the target annual bonus for calendar year 2020, contingent on certain performance conditions. The Company accrued $0.4 million during the quarter ended March 31, 2020 in relation to this arrangement. Leases See Note 8 for further discussion regarding lease commitments.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 15-SUBSEQUENT EVENTS On April 15, 2020, the FDA approved the Company’s new drug application for Jelmyto (mitomycin), formerly known as UGN-101, for pyelocalyceal solution, for adult patients with low-grade upper tract urothelial cancer. Jelmyto consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release RTGel technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means . In April 2020, the Company sold 700,000 ordinary shares under the ATM Sales Agreement, for gross proceeds of approximately $16.6 million. The net proceeds to the Company after deducting sales commissions to Cowen were approximately $16.1 million. The remaining capacity under the ATM Sales Agreement is approximately $83.4 million.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.
Use of Estimates	Use of Estimates The a i i n a i
Functional Currency	Functional The p l Accordingly, l n i a condensed a (
Cash and Cash Equivalents; Marketable Securities	Cash and Cash Equivalents; Marketable Securities The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. Cash and cash equivalents and marketable securities totaled $159.2 million as of March 31, 2020. The Company classifies its marketable securities as available-for-sale in accordance with the Financial Accounting Standards Board (“ Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company ’ The Company ’
Income Taxes	Income Taxes The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which we operate. Deferred l e n s a a The n l w a
Property and Equipment	Property and Equipment Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3-6.5 Furniture 5-16.5 Manufacturing equipment 2 Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 7 for further discussion regarding property and equipment.
Leases	Leases The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases. The Company accounts for leases in accordance with ASC Topic 842, “Leases” . Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments. The Company’s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option. Because most of the Company’s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The Company has lease agreements with lease and non-lease components. We applied the modified retrospective transition method and elected the transition option to use the effective date of January 1, 2019 as the date of initial application (“Transition Date”). ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, “Property, Plant, and Equipment”, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.
Revenues	Revenues To date, the Company has derived virtually all its revenues from its license and supply agreement (the “Allergan Agreement”) with Allergan Pharmaceuticals International Limited (“Allergan”), a wholly owned subsidiary of Allergan plc. Under the Allergan Agreement, the Company granted Allergan an exclusive license to develop, commercialize, and otherwise exploit products that contain reverse thermal hydrogel (“RTGel”) and agreed to supply Allergan with pre-clinical and clinical quantities of the RTGel product, also referred to as the RTGel Research and Development Expenses Research s i d a l l
Selling General and Administrative Expenses	Selling General and Administrative Expenses Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, executives, finance, commercial, medical affairs, business development, investor relations and human resources functions). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.
Research and Development Expenses
Share-Based Compensation	Share-Based Compensation Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (“RSU”) equaled the closing price of our ordinary shares on the grant date. The Company accounts for forfeitures as they occur according to the FASB’s Accounting Standards Update (ASU) 2016-09, Improvements to Employee Share-Based Payment Accounting. The Company elected to recognize compen s ation costs for awards conditioned only on conti n ued service that have a graded vesting schedule using the straight-line method and to value the awards based on the sin g le-option award approach.
Net Loss per Ordinary Share	Net Loss per Ordinary Share Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 requires the Company to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the Company’s current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the prior other-than-temporary impairment model. The Company applied the modified retrospective transition method as of the date of initial application, January 1, 2020, or the Transition Date. As of March 31, 2020, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Property and Equipment Useful Lives	Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3-6.5 Furniture 5-16.5 Manufacturing equipment 2

Other Financial Information (Ta

Other Financial Information (Tables)	3 Months Ended
	Mar. 31, 2020
Other Financial Information [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consist of the following as of March 31, 2020 and December 31, 2019 (in thousands): March 31, 2020 December 31, 2019 Accounts payable $ 4,152 $ 4,694 Accrued clinical expenses 235 399 Accrued research and development costs 1,696 2,644 Accrued selling, general and administrative expenses 2,057 2,767 Accrued other expense 360 682 Total accounts payable and accrued expenses $ 8,500 $ 11,186
Schedule of Interest and Other (Income) Expenses	Interest and other (income) expenses consisted of the following as of March 31, 2020 and 2019 (in thousands): Three Months Ended March 31, 2020 2019 Interest income $ (811 ) $ (1,010 ) Other finance expenses 43 21 Total finance income $ (768 ) $ (989 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of March 31, 2020 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable March 31, Identical Assets Inputs 2020 (Level 1) (Level 2) Marketable securities: US government $ 68,414 $ 68,414 $ — Corporate bonds 55,671 — 55,671 Commercial paper (1) 8,486 — 8,486 Money market funds (2) 13,904 13,904 — Certificates of deposit 1,788 — 1,788 $ 148,263 $ 82,318 $ 65,945 (1) $1.6 million is included within cash and cash equivalents on the condensed consolidated balance sheets (2) Included within cash and cash equivalents on the condensed consolidated balance sheets. Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2019 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable December 31, Identical Assets Inputs 2019 (Level 1) (Level 2) Marketable securities: US government $ 66,094 $ 66,094 $ — Corporate bonds 68,084 — 68,084 Commercial paper 7,658 — 7,658 Money market funds (1) 16,998 16,998 — Certificates of deposit 4,108 — 4,108 $ 162,942 $ 83,092 $ 79,850 (1) Included within cash and cash equivalents on the condensed consolidated balance sheets.

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2020
Investments Debt And Equity Securities [Abstract]
Summary of Marketable Securities	The following table summarizes the Company’s marketable securities as of March 31, 2020 (in thousands): Amortized Cost Basis Unrealized Gains Unrealized Losses Fair Value Marketable securities: US government $ 67,648 $ 766 $ — $ 68,414 Corporate bonds 56,135 75 (539 ) 55,671 Commercial paper 8,480 6 — 8,486 Money market funds 13,904 — — 13,904 Certificates of deposit 1,785 3 — 1,788 $ 147,952 $ 850 $ (539 ) $ 148,263
Summary of Fair Values of Marketable Securities by Contractual Maturity	The fair values of marketable securities by contractual maturity consist of the following (in thousands) March 31, 2020 December 31, 2019 Maturities within one year $ 108,126 $ 114,386 Maturities after one year through three years 40,137 48,556 $ 148,263 $ 162,942

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2020
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, consists of the following as of March 31, 2020 and December 31, 2019 (in thousands): March 31, 2020 December 31, 2019 Laboratory equipment $ 264 $ 259 Computer equipment and software 455 416 Furniture 596 544 Leasehold improvements 530 530 Manufacturing equipment 226 226 2,071 1,975 Less: accumulated depreciation and amortization (1,080 ) (998 ) Property and equipment, net $ 991 $ 977

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Components of Lease Cost	The components of lease cost for the three months ended March 31, 2020 were as follows (in thousands) Three Months Ended March 31, 2020 Operating lease cost $ 430 Sublease income (56 ) Variable lease cost 56 $ 430
Schedule of Amounts Recognized	The amounts recognized as of March 31, 2020 were as follows (in thousands): March 31, 2020 Right of use asset $ 3,433 Long-term lease liability 2,268 Other current liabilities 1,632
Schedule of Supplemental Information Related to Leases	Supplemental information related to leases for the periods reported is as follows (in thousands): Three Months Ended March 31, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 390 Right-of-use assets obtained in exchange for new operating lease liabilities 180 Weighted-average remaining lease term of operating leases 2.73 years Weighted-average discount rate of operating leases 5.47%
Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis	As of March 31, 2020 undiscounted cash flows to be received under the Company’s operating sublease on an annual basis was as follows (in thousands): Operating Leases Years ending December 31, Remainder of 2020 $ 61 2021 235 2022 243 2023 251 2024 49 2025 and thereafter — $ 839
Schedule of Sublease Income Recognized Net within Operating Expenses	Sublease income is recognized net within operating expenses. Sublease income for the three months ended March 31, 2020 was as follows (in thousands): Three Months Ended March 31, 2020 Sublease income from fixed lease payments $ 56 Sublease income from variable payments — $ 56

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations	The p condensed consolidated Three Months Ended March 31, 2020 2019 Research and development expenses 1,943 2,338 Selling, general and administrative expenses 5,674 5,109 $ 7,617 $ 7,447

Business and Nature of Operat_2

Business and Nature of Operations - Additional Information (Details)	3 Months Ended
	Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Date of incorporation	2004-04
Date of operating commencement	2016-02

Basis of Presentation - Additit

Basis of Presentation - Addititonal Information (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ 265,810	$ 228,017

Significant Accounting Polici_4

Significant Accounting Policies - Additional Information (Details) $ in Millions	Mar. 31, 2020USD ($)
Accounting Policies [Abstract]
Total cash and cash equivalents and marketable securities	$ 159.2

Significant Accounting Polici_5

Significant Accounting Policies - Property and Equipment Useful Lives (Details)	3 Months Ended
	Mar. 31, 2020
Computers and Software
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	3 years
Laboratory Equipment | Minimum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	3 years
Laboratory Equipment | Maximum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	6 years 6 months
Furniture | Minimum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	5 years
Furniture | Maximum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	16 years 6 months
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	2 years

Other Financial Information - S

Other Financial Information - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Other Financial Information [Abstract]
Accounts payable	$ 4,152	$ 4,694
Accrued clinical expenses	235	399
Accrued research and development costs	1,696	2,644
Accrued selling, general and administrative expenses	2,057	2,767
Accrued other expense	360	682
Total accounts payable and accrued expenses	$ 8,500	$ 11,186

Other Financial Information -_2

Other Financial Information - Schedule of Interest and Other (Income) Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Other Financial Information [Abstract]
Interest income	$ (811)	$ (1,010)
Other finance expenses	43	21
Total finance income	$ (768)	$ (989)

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	3 Months Ended
	Mar. 31, 2020USD ($)
Fair Value Disclosures [Abstract]
Fair value assets, transfers between level 1 to level 2	$ 0
Fair value assets, transfers between level 2 to level 1	0
Fair value liabilities, transfers between level 1 to level 2	0
Fair value liabilities, transfers between level 2 to level 1	0
Fair value assets, transfers into level 3	0
Fair value assets, transfers out of level 3	0
Fair value liabilities, transfers into level 3	0
Fair value liabilities, transfers out of level 3	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	$ 148,263	$ 162,942
Fair Value, Measurements, Recurring
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	148,263	162,942
Fair Value, Measurements, Recurring | US Government
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		66,094
Fair Value, Measurements, Recurring | Corporate Bonds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		68,084
Fair Value, Measurements, Recurring | Commercial Paper
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		7,658
Fair Value, Measurements, Recurring | Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		16,998
Fair Value, Measurements, Recurring | Certificates of Deposit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		4,108
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	82,318	83,092
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | US Government
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		66,094
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		16,998
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	65,945	79,850
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Corporate Bonds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		68,084
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Commercial Paper
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		7,658
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Certificates of Deposit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		$ 4,108
Fair Value, Measurements, Recurring | US Government
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	68,414
Fair Value, Measurements, Recurring | US Government | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	68,414
Fair Value, Measurements, Recurring | Corporate Bonds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	55,671
Fair Value, Measurements, Recurring | Corporate Bonds | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	55,671
Fair Value, Measurements, Recurring | Commercial Paper
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	8,486
Fair Value, Measurements, Recurring | Commercial Paper | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	8,486
Fair Value, Measurements, Recurring | Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	13,904
Fair Value, Measurements, Recurring | Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	13,904
Fair Value, Measurements, Recurring | Certificates of Deposit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	1,788
Fair Value, Measurements, Recurring | Certificates of Deposit | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	$ 1,788

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Details) $ in Millions	Mar. 31, 2020USD ($)
Commercial Paper
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 1.6

Marketable Securities - Summary

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Marketable securities:
Amortized Cost Basis	$ 147,952
Unrealized Gains	850
Unrealized Losses	(539)
Fair Value	148,263	$ 162,942
US Government
Marketable securities:
Amortized Cost Basis	67,648
Unrealized Gains	766
Fair Value	68,414
Corporate Bonds
Marketable securities:
Amortized Cost Basis	56,135
Unrealized Gains	75
Unrealized Losses	(539)
Fair Value	55,671
Commercial Paper
Marketable securities:
Amortized Cost Basis	8,480
Unrealized Gains	6
Fair Value	8,486
Money Market Funds
Marketable securities:
Amortized Cost Basis	13,904
Fair Value	13,904
Certificates of Deposit
Marketable securities:
Amortized Cost Basis	1,785
Unrealized Gains	3
Fair Value	$ 1,788

Marketable Securities - Additio

Marketable Securities - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)Security
Investments Debt And Equity Securities [Abstract]
Accrued interest receivable	$ 600
Available-for-sale debt securities, unrealized gain position	300
Available-for-sale debt securities, unrealized loss position	$ 33,700
Available-for-sale debt securities, number of securities in unrealized loss position | Security	41
Other-than-temporary impairment Loss, debt securities, portion recognized in earnings	$ 0

Marketable Securities - Summa_2

Marketable Securities - Summary of Fair Values of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Available For Sale Securities Debt Maturities Fair Value [Abstract]
Maturities within one year	$ 108,126	$ 114,386
Maturities after one year through three years	40,137	48,556
Debt securities, Available-for-sale	$ 148,263	$ 162,942

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment	$ 2,071	$ 1,975
Less: accumulated depreciation and amortization	(1,080)	(998)
Property and equipment, net	991	977
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment	264	259
Computers and Software
Property Plant And Equipment [Line Items]
Property and equipment	455	416
Furniture
Property Plant And Equipment [Line Items]
Property and equipment	596	544
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment	530	530
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and equipment	$ 226	$ 226

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 0.1	$ 0.1

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended
	Nov. 30, 2019	Apr. 30, 2018	Sep. 30, 2017	Mar. 31, 2020
Lessee Lease Description [Line Items]
Operating leases, existence of option to extend				true
Operating leases, options to extend lease term, description				UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022.
Operating leases, options to extend lease term				3 years
Operating lease extended lease expiration, month and year				2022-08
Remaining rental payments to be received over the lease term				$ 56,000
Impairment losses on operating leases				$ 0
Minimum
Lessee Lease Description [Line Items]
Lease expiration year				2019
Maximum
Lessee Lease Description [Line Items]
Lease expiration year				2023
UroGen Pharma Inc. | New York
Lessee Lease Description [Line Items]
Lease commencement period, month and year			2017-10
Lease termination period, month and year			2021-02
Remaining contractual obligation				$ 600,000
UroGen Pharma Inc. | Los Angeles, California
Lessee Lease Description [Line Items]
Lease termination period, month and year		2024-03
Remaining contractual obligation				1,100,000
Lease commencement date		Jul. 10, 2018
Proceeds from tenant allowance		$ 200,000
Lessee operating sublease commencement date	Jan. 1, 2020
Lessee operating sublease termination period, month and year	2024-03
Remaining rental payments to be received over the lease term				800,000
UroGen Pharma Inc. | Princeton, NJ | Lease Agreement
Lessee Lease Description [Line Items]
Remaining contractual obligation				$ 1,600,000
Lease commencement date	Nov. 29, 2019
Lease term	38 months

Leases - Components of Lease Co

Leases - Components of Lease Cost (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Leases [Abstract]
Operating lease cost	$ 430
Sublease income	(56)
Variable lease cost	56
Lease, Cost	$ 430

Leases - Schedule of Amounts Re

Leases - Schedule of Amounts Recognized (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Right of use asset	$ 3,433	$ 3,735
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent
Long-term lease liability	$ 2,268	$ 2,604
Other current liabilities	$ 1,632
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Information Related to Leases (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 390
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 180
Weighted-average remaining lease term of operating leases	2 years 8 months 23 days
Weighted-average discount rate of operating leases	5.47%

Leases - Schedule of Undiscount

Leases - Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis (Details) $ in Thousands	Mar. 31, 2020USD ($)
Leases [Abstract]
Remainder of 2020	$ 61
2021	235
2022	243
2023	251
2024	49
Lessee operating sublease payments to be received	$ 839

Leases - Schedule of Sublease I

Leases - Schedule of Sublease Income Recognized Net within Operating Expenses (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Leases [Abstract]
Sublease income from fixed lease payments	$ 56
Sublease income from payments	$ 56

License and Collaboration Agr_2

License and Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Nov. 30, 2019	Mar. 31, 2020	Dec. 31, 2019
Research And Development Arrangement Contract To Perform For Others [Line Items]
Payments on license agreement milestone in acquired in process research and development expenses		$ 10,000,000
Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront fee	$ 10,000,000
Maximum amount payable upon achieving certain clinical development and regulatory milestones	115,000,000
Maximum amount payable upon achieving certain commercial milestones	$ 85,000,000
License agreement milestone in acquired in-process research and development expenses			$ 10,000,000
Agenus Agreement | After First Commercial Sale of Licensed Product
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement expiration term	15 years
Maximum | Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty ranging on net sales of licensed products	20.00%
Minimum | Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty ranging on net sales of licensed products	14.00%
Allergan | License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments received for licensing agreement		25,000,000
Allergan | License Agreement | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement additional milestone payments eligible to receive		$ 200,000,000

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended
	Dec. 31, 2019	Jan. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Class Of Stock [Line Items]
Ordinary shares, shares authorized	100,000,000		100,000,000
Ordinary shares, issued	21,026,184		21,212,940
Ordinary shares, outstanding	21,026,184		21,212,940
Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs				$ 161,447,000
Issuance of ordinary shares, net of issuance expenses				$ 161,974,000
Cowen and Company Limited Liability Company | ATM Sales Agreement
Class Of Stock [Line Items]
Issuance of ordinary shares, net of issuance expenses			$ 0
Cowen and Company Limited Liability Company | Maximum | ATM Sales Agreement
Class Of Stock [Line Items]
Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs	$ 100,000,000
Underwritten Public Offering
Class Of Stock [Line Items]
Issuance of ordinary shares, shares		4,207,317
Additional ordinary shares exercised under underwriters option to purchase at the public offering price		548,780
Issuance of ordinary shares, price per share		$ 41
Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs		$ 161,400,000

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details)	Jan. 03, 2019USD ($)$ / sharesshares	Oct. 12, 2018shares	Jan. 01, 2018shares	Dec. 31, 2019USD ($)	Jun. 30, 2019USD ($)$ / sharesshares	Mar. 31, 2017shares	Mar. 31, 2020USD ($)shares	Mar. 31, 2019USD ($)	May 31, 2019shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense | $							$ 7,617,000	$ 7,447,000
Unrecognized compensation cost of options and RSUs | $							$ 50,800,000
Expected to be recognized over a weighted average period							1 year 11 months 12 days
Options | General and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense | $				$ 900,000
Options | Elizabeth Barrett
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option to purchase of ordinary shares	277,432
Exercise price of option to purchase of ordinary shares | $ / shares	$ 47.57
Options | Non-employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted, expected term					10 years
Awards vesting period					1 year
Number of stock options approved for grants					70,000
Stock options granted					10,000
Exercise of option to ordinary shares conversion ratio					1
Stock option exercise | $ / shares					$ 34.83
Estimated fair value of options granted | $					$ 1,900,000
Options | Chairman of Board of Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted					10,000
Options | Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage							33.00%
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period							2 years
Share-based compensation expense | $				$ 0
Restricted Stock Units (RSUs) | Elizabeth Barrett
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option to purchase of ordinary shares	317,065
Restricted Stock Units (RSUs) | Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage							33.00%
2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of ordinary share issuable under the 2017 incentive plan						1,400,000	5,600,000
Number of ordinary shares reserved for issuance, percentage							12.00%
Increase in number of ordinary share issuable under the 2017 incentive plan		1,900,000	250,167
Stock Options and Restricted Stock Units (RSUs) | Elizabeth Barrett
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value | $	$ 24,100,000
Plan | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period							3 years
Combined voting power percentage							10.00%
Ordinary Shares | 2019 Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options approved for grants									900,000
Ordinary Shares | 2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of ordinary share issuable under the 2017 incentive plan		3,550,167	1,650,167
Maximum | Plan | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted, expected term							10 years
Minimum | Plan | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of stock options as percentage of fair market value of shares on grant date							100.00%
Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power							110.00%

Share Based Compensation - Sche

Share Based Compensation - Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	$ 7,617	$ 7,447
Research and Development Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	1,943	2,338
Selling, General and Administrative Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	$ 5,674	$ 5,109

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)
Commitments And Contingent Liabilities [Line Items]
Accrued bonus payable	$ 0.4
IIA
Commitments And Contingent Liabilities [Line Items]
Royalty amount payable	$ 6.6
Maximum percentage of commitment to continue employment of research and development jobs	75.00%
Maximum term for commitment to continue employment of research and development jobs	3 years

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 30, 2020	Mar. 31, 2020	Mar. 31, 2019
Subsequent Event [Line Items]
Issuance of ordinary shares, net of issuance expenses			$ 161,974,000
Cowen and Company Limited Liability Company | ATM Sales Agreement
Subsequent Event [Line Items]
Issuance of ordinary shares, net of issuance expenses		$ 0
Subsequent Event | Cowen and Company Limited Liability Company | ATM Sales Agreement
Subsequent Event [Line Items]
Number of ordinary shares sold	700,000
Issuance of ordinary shares, net of issuance expenses	$ 16,600,000
Net proceeds from ordinary shares after deducting sales commissions	16,100,000
Remaining capacity	$ 83,400,000